Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback